Radius Health, Inc. (NASDAQ:RDUS) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03), Briefing.com reports. The company had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same period in the prior year, the company posted ($1.07) earnings per share.
Shares of Radius Health (NASDAQ RDUS) traded down $1.29 during trading hours on Friday, reaching $29.56. The company’s stock had a trading volume of 2,824,590 shares, compared to its average volume of 954,239.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.com-unik.info/2017/11/03/radius-health-inc-rdus-issues-quarterly-earnings-results-misses-estimates-by-0-03-eps.html.
Several research firms recently commented on RDUS. Cantor Fitzgerald reissued a “buy” rating and issued a $58.00 price objective on shares of Radius Health in a research note on Friday. Jefferies Group LLC dropped their target price on Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a report on Friday. Canaccord Genuity set a $85.00 target price on Radius Health and gave the company a “buy” rating in a report on Monday, July 17th. BidaskClub cut Radius Health from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, Zacks Investment Research upgraded Radius Health from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. Radius Health currently has a consensus rating of “Hold” and a consensus price target of $51.00.
In other Radius Health news, major shareholder Growth N. V. Biotech purchased 150,000 shares of the stock in a transaction dated Thursday, August 10th. The stock was acquired at an average cost of $34.97 per share, for a total transaction of $5,245,500.00. Following the acquisition, the insider now owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Growth N. V. Biotech purchased 50,000 shares of the stock in a transaction dated Wednesday, October 25th. The shares were acquired at an average price of $32.85 per share, with a total value of $1,642,500.00. Following the completion of the acquisition, the insider now owns 5,548,799 shares in the company, valued at approximately $182,278,047.15. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 519,100 shares of company stock valued at $17,970,882. Company insiders own 15.00% of the company’s stock.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
What are top analysts saying about Radius Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Radius Health Inc. and related companies.